U.S. markets closed

PharmaCyte Biotech, Inc. (PMCB)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.0800-0.0200 (-0.95%)
At close: 04:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected


Previous Close2.1000
Bid0.9668 x 1000
Ask2.1400 x 1800
Day's Range2.0707 - 2.1250
52 Week Range1.9200 - 3.2300
Avg. Volume15,935
Market Cap17.921M
Beta (5Y Monthly)-0.17
PE Ratio (TTM)N/A
EPS (TTM)-0.9000
Earnings DateMar 11, 2024 - Mar 16, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for PMCB

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • PharmaCyte Biotech, Inc.
    HALO: Raising target price to $38.00HALOZYME THERAPEUTICS INC has an Investment Rating of HOLD; a target price of $38.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
    Fair Value
    Economic Moat
    10 days agoArgus Research
View more
  • Business Wire

    PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women’s Health Innovator Femasys, Inc.

    LAS VEGAS, November 15, 2023--PharmaCyte Biotech, Inc. (Nasdaq: PMCB) ("PharmaCyte" or the "Company") announces it has made a $5 million investment in Femasys, Inc. (Nasdaq:FEMY) ("Femasys"), a biomedical company focused on meeting significant unmet needs for women worldwide. Femasys offers a broad portfolio of in-office, accessible solutions, including a lead late-stage product candidate and innovative therapeutic and diagnostic products. This is the Company’s first investment in externally dev

  • GlobeNewswire

    Femasys Inc. Secures Additional Financing with Strategic Investment from Investors led by PharmaCyte Biotech

    - $6.85 million upfront investment provides $23 million total cash runway into second half 2025 - - Financing allows for focused commercial team to bring Femasys’ infertility-related products to women in the U.S. - - Additional financing supports the advancement of Femasys’ lead product candidate, FemBloc® for permanent birth control, to initial clinical data readout - ATLANTA, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting significant unme

  • Business Wire

    PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology

    LAS VEGAS, October 31, 2023--PharmaCyte Biotech, Inc. (Nasdaq: PMCB) ("PharmaCyte" or the "Company") provides an update on its investigation of its Cell-in-a-Box technology and initial next steps in development. Following a comprehensive scientific review of amassed data, the Company is in the process of requesting a meeting with the U.S. Food and Drug Administration (FDA) for guidance on further development of the technology. The meeting is expected to occur during the first quarter of 2024. In